Ed Harris

AI x Bio | CEO at Ligo Biosciences | Prev. Medicine @UniofOxford

[Ed Harris @edharris]

@GabriCorso @chaitjo @boltz_bio Cool to see the models are broadly accessible even if not open. Feel like that’s getting much rarer these days.

[Ed Harris @edharris]

@kudkudakpl @MoleculeOne @OpenAI This is cool!

[Kenny Workman @kenbwork]

Introducing EpiBench, an agentic benchmark for practical epigenomics analysis.

106 evaluations span CUT&Tag/CUT&RUN, ATAC-seq, ChIP-seq, and DNA methylation workflows. The best agent–harness pair passes 45.0% of evaluations.

Evaluations reflect the assay outputs scientists use in practice. A task may depend on alignment files, peak calls, methylation tables, QC metrics, sample metadata, genomic annotations, or downstream summaries. Solving them requires a mix of coding, data analysis, and scientific judgment.

Ground truth is hard to define even for short-horizon scientific tasks. Alternative task interpretations can produce multiple plausible answers. Candidate tasks are hardened through manual quality control. We remove prompts that over-specify the method, answers that can be solved with general literature knowledge, and ground truths that fail to reproduce under peer reproduction.

Short-horizon tasks are the current frontier for scientific agents in epigenomics. Before models can own deeper biological reasoning, they need to become reliable at local assay-specific decisions.

[Ed Harris @edharris]

@s00k1m Love it !

[Soo Kim @s00k1m]

don’t type pymol commands urself, now there’s co-pymol

available for claude code and cursor ⬇️

[Arda Göreci @ArdaGoreci]

Excited to share more of our technical notes in the spirit of open-research. Blog 2: How Muon Lost its Geometry

As Muon spread from speedruns to LLM-scale, it lost the µP scaling rule that keeps the best LR as width changes. The bug ships in PyTorch and Optax 😱. (1/n)

[Deniz Kavi @kavi_deniz]

We’re proud to share that @TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models trained on over $1B worth of Lilly proprietary data to the biotech ecosystem.

Tamarind will power TuneLab’s scalable drug discovery workflows and model inference.

[Ed Harris @edharris]

@ArdaGoreci @owl_posting sadly not

[Ed Harris @edharris]

@jontycorrin 💔

[Ed Harris @edharris]

suuuuuurely you dont need to be this cautious.

[Ed Harris @edharris]

Interesting work! Im curious where else you think these models will be halted in bio? It seems like there are lots of areas that LLMs cant venture in to yet, I wonder if more tools will be the way we start to teach these models about more and more areas of biology (beyond just accessing data)

[Ed Harris @edharris]

@matt_is_nice Yeah, I think domain specific tooling in bio is going to become much more important.

[Ed Harris @edharris]

@michellearning @barisakis Cool, how is best to sign up? Are you running customer experiments already? We have lots of CRO planned experiments I’d love to move over !

[Ed Harris @edharris]

@michellearning @barisakis I see! When are the next tours? I’d love to see it in person !!

[Ed Harris @edharris]

@michellearning @barisakis Haha. This was a genuine question, not a snarky remark. Is this lab number 2 you’re opening?

[Mgoes (bio/acc 🤖💉) @m_goes_distance]

I have never been this bullish on biotech.

- peptide adoption going vertical :what started in grey markets is now heading toward federal policy in under 18 months
- the first human trial designed to reverse cellular aging is running right now. Results expected this year.
- AI is designing drugs that are outperforming anything a human research team has produced
- RAS just got drugged after 40 years of scientists calling it undruggable

by the time these reach the consumer at $100 a pop, the window to move early will already be closed.

that's exactly why Superhuman Fund II is backing this wave now.

[Ed Harris @edharris]

@AppleHelix I don't this he is betting on the future of bio being representative of todays pharma market...

[Ed Harris @edharris]

@nanogenomic @proteinrosh @ArdaGoreci

[Emily @eggywarbs]

@ArdaGoreci Brought to you by our protein cowboy